Atossa Therapeutics
ATOS
16 hedge funds and large institutions have $991K invested in Atossa Therapeutics in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
14% more funds holding
Funds holding: 14 → 16 (+2)
0.58% less ownership
Funds ownership: 1.27% → 0.69% (-0.58%)
16% less capital invested
Capital invested by funds: $1.18M → $991K (-$185K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$271K |
| 2 |
Jane Street
New York
|
+$51.4K |
| 3 |
VF
Virtu Financial
New York
|
+$30.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$29.7K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$359 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$240K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$53K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$20K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
ATOS Hedge Fund Activity: Q3 2018 in Review
16 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2018, worth a combined $991K — down 16% from $1.18M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATOS positions and 4 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $271K. The largest seller was Anson Funds Management, exiting entirely with an estimated $240K sold.
- 16 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2018, up from 14 in Q2 2018.
- Funds reported $991K of Atossa Therapeutics stock for Q3 2018, down 16% quarter-over-quarter.
- 6 funds opened new Atossa Therapeutics positions in Q3 2018 and 4 closed out, a net change of +2 holders.
- The largest Atossa Therapeutics buyer in Q3 2018 was Sabby Management, an estimated $271K added.
- The largest Atossa Therapeutics seller in Q3 2018 was Anson Funds Management, an estimated $240K sold.
Based on aggregated 13F filings for Q3 2018.